

Publication list of Akiko Miki as of July 14th, 2014 (Only written in English)

I. Original Articles

1. Usui S, Oveson BC, Lee SY, Jo YJ, Yoshida T, Miki A, Miki K, Iwase T, Lu L, Campochiaro PA. NADPH oxidase plays a central role in cone cell death in retinitis pigmentosa. *J Neurochem*. 2009 Aug;110(3):1028-37.
2. Miki K, Miki A, Matsuoka M, Muramatsu D, Hackett SF, Campochiaro PA. Effects of intraocular ranibizumab and bevacizumab in transgenic mice expressing human vascular endothelial growth factor. *Ophthalmology*. 2009 Sep;116(9):1748-54.
3. Miki A, Miki K, Ueno S, Wersinger DM, Berlinicke C, Shaw GC, Usui S, Wang Y, Zack DJ, Campochiaro PA. Prolonged blockade of VEGF receptors does not damage retinal photoreceptors or ganglion cells. *J Cell Physiol*. 2010 Jul;224(1):262-72.
4. Yanagisawa S, Kondo N, Miki A, Matsumiya W, Kusuhara S, Tsukahara Y, Honda S, Negi A. A common complement C3 variant is associated with protection against wet age-related macular degeneration in a Japanese population. *PLoS One*. 2011;6(12):e28847.
5. Yanagisawa S, Kondo N, Miki A, Matsumiya W, Kusuhara S, Tsukahara Y, Honda S, Negi A. Difference between age-related macular degeneration and polypoidal choroidal vasculopathy in the hereditary contribution of the A69S variant of the age-related maculopathy susceptibility 2 gene (ARMS2). *Mol Vis*. 2011;17:3574-82.
6. Miki A, Honda S, Kondo N, Negi A. The association of age-related maculopathy susceptibility 2 (ARMS2) and complement factor H (CFH) variants with two angiographic subtypes of polypoidal choroidal vasculopathy. *Ophthalmic Genet*. 2013 Sep;34(3):146-50.
7. Miki A, Kanamori A, Negi A, Naka M, Nakamura M. Loss of aquaporin 9 expression adversely affects the survival of retinal ganglion cells. *Am J Pathol*. 2013 May;182(5):1727-39.
8. Miki A, Honda S, Kojima H, Nishizaki M, Nagai T, Fujihara M, Uenishi M, Kita M, Kurimoto Y, Negi A; Hyogo Macular Disease Study Group. Visual outcome of photodynamic therapy for typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy over 5 years of follow-up. *Jpn J Ophthalmol*. 2013 May;57(3):301-7.
9. Miki A, Honda S, Nagai T, Tsukahara Y, Negi A. Effects of oral bisphosphonates on myopic choroidal neovascularisation over 2 years of follow-up: comparison with anti-VEGF therapy and photodynamic therapy. A pilot study. *Br J Ophthalmol*. 2013 Jun;97(6):770-4.
10. Shmueli RB, Ohnaka M, Miki A, Pandey NB, Lima e Silva R, Koskimaki JE, Kim J, Popel AS, Campochiaro PA, Green JJ. Long-term suppression of ocular neovascularization by intraocular injection of biodegradable polymeric particles containing a serpin-derived peptide. *Biomaterials*. 2013 Oct;34(30):7544-51.

11. Iwase T, Fu J, Yoshida T, Muramatsu D, Miki A, Hashida N, Lu L, Oveson B, Lima e Silva R, Seidel C, Yang M, Connelly S, Shen J, Han B, Wu M, Semenza GL, Hanes J, Campochiaro PA. Sustained delivery of a HIF-1 antagonist for ocular neovascularization. *J Control Release*. 2013 Dec 28;172(3):625-33.
12. Miki A, Kondo N, Yanagisawa S, Bessho H, Honda S, Negi A. Common variants in the complement factor H gene confer genetic susceptibility to central serous chorioretinopathy. *Ophthalmology*. 2014 May;121(5):1067-72.
13. Matsumiya W, Honda S, Yanagisawa S, Miki A, Nagai T, Tsukahara Y. Evaluation of clinical and genetic indicators for the early response to intravitreal ranibizumab in exudative age-related macular degeneration. *Pharmacogenomics*. 2014 Apr;15(6):833-43.
14. Honda S, Miki A, Yanagisawa S, Matsumiya W, Nagai T, Tsukahara Y. Comparison of the Outcomes of Photodynamic Therapy between Two Angiographic Subtypes of Polypoidal Choroidal Vasculopathy. *Ophthalmologica*. 2014 Jun 27. [Epub ahead of print]